Looking For Ebola Virus Meds? WHO Recommends These Two Antibody Treatments
The World Health Organization (WHO) has published its first guideline for Ebola virus disease therapeutics, with new recommendations for using…
Cel-Sci Corporation Shares Move Lower; Adam Feuerstein Tweets ‘$CVM posted results from Multikine ph3 study on clinicaltrials gov today, confirming the failure….Placebo patients lived longer. This drug is not getting approved, anywhere.’
https://twitter.com/adamfeuerstein/status/1560652668212719616
Testosterone-Drug Focused Penny Stock Falls On Bankruptcy Fears
Clarus Therapeutics Holdings Inc (NASDAQ:CRXT) has implemented a 40% reduction in staff as it evaluates strategic alternatives and terminates certain research…
Bavarian Nordic Recruits US Firm For Packaging Services For Its Monkeypox Vaccine
Bavarian Nordic A/S (OTC:BVNRY) signed up a U.S.-based manufacturer to fill and finish its Jynneos monkeypox vaccine, and the production is…
Applied Biology Sponsored Study Titled ‘Treatment for Post Acute COVID-19 Syndrome’ Posted To ClinicalTrials.gov; Study Not Yet Recruiting; Jupiter Wellness Is A Collaborator On Study
https://clinicaltrials.gov/ct2/show/NCT05507372
Axsome’s Depression Candidate Scores FDA Nod, Stock Surges To 52-High
The FDA has approved Axsome Therapeutics Inc’s (NASDAQ:AXSM) Auvelity (dextromethorphan HBr -bupropion HCl) extended-release tablets for major depressive disorder (MDD) in…
Axsome Shares Shoot Higher As FDA Approves Major Depressive Disorder Candidate
The U.S. Food and Drug Administration (FDA) has approved Axsome Therapeutics’ (NASDAQ: AXSM) lead asset AUVELITY (dextromethorphan HBr -bupropion HCl) extended-release tablets for the treatment of major depressive disorder (MDD) in adults.